News & Events
Insight Genetics, Inc. today announced the launch of its proprietary Insight TNBCtype™, a new test for categorizing triple negative breast cancer (TNBC) tumors into distinct molecular subtypes through its wholly owned CLIA- and CAP-accredited lab, Insight Molecular Labs. Insight TNBCtype™, the first and only CLIA-validated assay for TNBC molecular subtyping, will enable prospective clinical trials with pharmaceutical, biotechnology, and academic medical institutions and advance targeted therapies for TNBC patients, addressing a significant unmet need in oncology today. The test will be featured in posters presented at the 2018 San Antonio Breast Cancer Symposium from December 4-8, 2018, in San Antonio, Texas.
Cancers Article Compares Performance of a RT-PCR Assay to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer
Cancers publishes article "Performance of a RT-PCR Assay in Comparison to FISH and Immunohistochemistry for the Detection of ALK in Non-Small Cell Lung Cancer." Click here to read more.
JCO Precision Oncology Case Report Highlights Use of Insight TNBCtype to Classify Triple Negative Breast Cancer Tumor
JCO Precision Oncology recently published "Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis." Click here to read more.
Insight Genetics Presented Presents Posters on Immune Cell Involvement in TNBC at San Antonio Breast Cancer Symposium
Insight Genetics, Inc.’s proprietary Insight TNBCtype™ algorithm was featured in two posters on triple negative breast cancer (TNBC) presented on December 7 at the 2016 San Antonio Breast Cancer Symposium (SABCS).
2015 was an exciting year for Insight Genetics with the formation of new partnerships, continued collaboration with existing partners, expansion of our leadership team, the launch of a CLIA-validated assay for non-small cell lung cancer (NSCLC), presentation of new research findings on triple negative breast cancer (TNBC), and new funding to continue the advancement of the company’s TNBC and NSCLC programs. We look forward to an eventful 2016 as we continue to clinically validate and commercialize our breast and lung cancer assays, adapt these assays for compatibility with liquid biopsies and broader, multi-biomarker panels, expand collaborations with key academic institutions and commercial partners, and extend our services to the pharmaceutical industry.